Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13234MR)

This product GTTS-WQ13234MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13234MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7719MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ11019MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ4773MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ10606MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ2238MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ2116MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ1632MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW